Researchers present long-term results of RTOG 0236, confirming good primary tumor control and positive 5-year survival rates for patients with inoperable lung cancer. The study found a 40% 5-year survival rate, with seven percent estimated five-year primary tumor failure rate.
A combination of chemotherapy drugs cisplatin and pemetrexed improved survival rates and response to advanced cervical cancer by 31% compared to standard alternative, while being less toxic to patients. Adding bevacizumab further increased patient survival, suggesting the cocktail may offer further benefits.
A study of over 41,000 patients with stage I and II Hodgkin's Disease found that those receiving consolidated radiation therapy had a higher 10-year survival rate of 84 percent compared to 76 percent for non-RT recipients. The data also showed a decrease in RT utilization, highlighting ongoing disparities in treatment.
A study from the University of Texas M. D. Anderson Cancer Center found that women with Stage I disease who underwent breast conserving therapy (BCT) had superior five-year overall survival rates compared to those who received a mastectomy or BCS, even after adjusting for other risk factors.
Patients with advanced laryngeal cancer who underwent surgery had significantly better disease-specific and overall survival rates compared to those treated with nonsurgical chemoradiation. The study analyzed data from over 5,000 patients diagnosed between 1992 and 2009.
Research suggests that autophagy may be both beneficial and detrimental to neuronal survival after stroke. The study proposes that autophagy has dual effects on neuronal survival, highlighting the need for further investigation into its therapeutic potential.
A new Arizona EMS system dramatically increased cardiac arrest survival rates, with a 60% increase in four-year period. The system sent patients to specialized cardiac receiving centers, significantly improving neurological outcomes and survival chances.
A new study found large differences in survival rates of 12 shark species caught by commercial longline fishing operations. The most vulnerable species include bigeye thresher, dusky, and scalloped hammerhead sharks.
A recent study published in JNCI: Journal of the National Cancer Institute found that contralateral prophylactic mastectomy (CPM) may confer only a marginal life expectancy benefit depending on the type and stage of cancer. The procedure was more beneficial for younger women and those with stage I and ER-negative breast cancer.
A large population-based study of European adults with blood cancers found that regional differences in treatment and care quality contribute to varying survival rates. The study analyzed data from 30 cancer registries covering all patients diagnosed in 20 European countries between 1997 and 2008.
Researchers evaluated 459 patients who underwent transcatheter valve-in-valve implantation for failed bioprosthetic aortic valves. The study found that survival rates were associated with surgical valve size and mechanism of failure, with patients experiencing better outcomes for regurgitation compared to stenosis.
Researchers at Sanford-Burnham Medical Research Institute have identified a chemical switch controlling neuron generation and survival in the brains of Alzheimer's patients and stroke victims. This switch, MEF2, may be a potential therapeutic target to protect against neuronal loss in various neurodegenerative diseases.
A phase 3 study of everolimus failed to improve overall survival in patients with advanced hepatocellular carcinoma, a type of liver cancer. In contrast, sorafenib is the only systemic therapy shown to significantly improve overall survival.
The phase III RECOURSE trial found that TAS-102 improves overall and progression-free survival in patients with metastatic colorectal cancer refractory to standard therapies. The study showed a median overall survival of 7.1 months for TAS-102, compared to 5.3 months for placebo.
A nested case-control study found an association between older maternal age at birth of the last child and exceptional longevity. Women who had their last child beyond age 33 years had twice the odds for survival, with an increased risk tempered by having multiple children.
A study found that selumetinib improved cancer progression-free survival time and tumor response rate in patients with advanced uveal melanoma, but had no impact on overall survival. Treatment-related adverse events were common, affecting nearly all patients.
Despite progress in treating head and neck cancer, MU researchers found that prognosis for African-Americans has not improved over the last 40 years. The study analyzed data from 1973 to 2010, showing a significantly decreased five-year overall survival rate of 41.8 percent for African-Americans compared to 60.8 percent for Caucasians.
A study published in PLOS ONE found that feeding juvenile corals prior to transplantation significantly improved their survival rates. Coral recruits fed with a higher amount of food grew faster and larger than unfed corals, leading to higher post-transplantation survivorship.
A chemotherapy regimen after radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas by an average of 5.5 years compared to radiation alone. The study, RTOG 9802, also found better outcomes for patients with oligodendroglioma and females.
A retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS) found a significant benefit. Patients treated with adjuvant chemotherapy had an improved median overall survival, with a 23% increase compared to those not treated.
Wind speeds on migration predicted annual survival, male arrival date, female egg laying, and productivity of yellow warblers. Higher westerly wind speeds associated with lower apparent annual survival due to increased in-flight mortality risk.
Researchers at Henry Ford Hospital identified specific genes associated with improved survival rates among patients with glioblastoma, the most deadly form of brain tumor. The study found that patients over 70 were more likely to survive longer and that gender differences played a role in short-term survival rates.
A Kaiser Permanente study found that radiation treatment significantly reduced the risk of Merkel cell carcinoma recurrence, with no impact on survival rates. The study's results also showed associations between immunosuppression and advanced tumors, as well as lymph node evaluation, and worse survival outcomes.
A new study finds that higher sleep efficiency is associated with lower mortality in women with advanced breast cancer. Mean survival was 68.9 months for efficient sleepers compared to 33.2 months for those with poor sleep efficiency.
A new study found that poor global QOL scores do not predict worse survival in high-risk lung cancer patients undergoing sublobar resection, contradicting prior studies. Patients with breathing problems at baseline or decline in function after surgery had poorer overall survival.
Clinical trials show chemotherapy before surgery improves muscle-invasive bladder cancer survival. Chemotherapy after surgery also increases survival rates, with a significant improvement over time.
A systematic review of 47 studies found that surveillance screening for hepatocellular carcinoma (HCC) in cirrhosis patients led to earlier detection, curative treatment, and longer survival. The pooled 3-year survival rate among screened patients was 50.8%, compared to 27.9% among unscreened patients.
A study of 999 patients found that low-dose aspirin use after colon cancer diagnosis was associated with improved overall survival, particularly among those with HLA class I antigen expression. The molecular mechanisms underlying this effect are not fully understood.
A recent study found that female hormone therapy, particularly estrogen plus progesterone, significantly improved survival among women with non-small cell lung cancer. The combination of hormone therapy and long-term use showed the most notable improvements in median survival time.
A Phase III clinical trial found no significant improvement in overall survival or progression-free survival with bevacizumab treatment for new glioblastoma patients. Researchers also observed increased symptoms and neurocognitive decline among non-progressing patients treated with bevacizumab.
A new study found that despite improved cancer treatments, survival rates for Blacks and Hispanics have not increased significantly. The disparity is largely attributed to factors such as poorer health and lower socioeconomic status, leading to barriers in healthcare access.
A simple protein test may help predict survival rates for patients with head and neck cancer by identifying HPV-positive tumours. This test could allow doctors to choose more appropriate treatments, leading to better outcomes for patients.
A 10.4-year median follow-up study by EORTC trial 22921 found that adjuvant chemotherapy does not improve survival or disease-free survival for cT3-resectable T4 M0 rectal cancer patients, highlighting the need for new treatment strategies.
A new study found that combining high-dose interleukin-2 therapy with personalized tumor cell-based immunotherapy significantly improves patient survival rates. The treatment approach, which activates patients' immune systems using their own tumor cells, outperforms IL-2 alone in extending survival.
Researchers at Cedars-Sinai have discovered a 10-gene biomarker panel that can identify the aggressiveness of ovarian cancer, predict survival outcomes, and inform novel therapeutic strategies. The study suggests that this biomarker panel may have predictive value and biological relevance for treating patients with ovarian cancer.
A study found that genetic alterations in the PAX gene family may explain head and neck cancer survival disparities between African-American and non-Latino white men. The research identified differential genomic and epigenomic alterations in PAX, NOTCH, and TP53 pathways between the two groups.
Research reveals racial disparities in pediatric liver transplant survival, with higher graft and patient survival rates among white children. Socioeconomic differences also contribute to these disparities, highlighting the need for further investigation and intervention.
A recent study published in The Lancet Oncology found that cancer survival rates still differ significantly between European countries, with Nordic countries having the best survival rates for most cancers. However, there is evidence of narrowing gaps between east and west, particularly for breast and prostate cancers.
Scientists at Fred Hutchinson Cancer Center developed a method to count tumor-infiltrating T lymphocytes reliably and quickly, which correlates with improved survival rates. The technology has the potential to predict treatment response, cancer recurrence, and disease-free survival earlier and more effectively.
Survivors with a history of smoking have poorer survival rates and are more likely to experience disease progression, relapse, or spread. Heavier pack-years smoked correlate with increased risk of death.
Studies reveal that comorbidities like diabetes and cardiovascular disease decrease one- and five-year survival rates for breast cancer patients. This indicates the need to reevaluate treatment approaches and optimize care for patients with concurrent diseases.
The EORTC trial found that perioperative chemotherapy with FOLFOX4 increases progression-free survival compared to surgery alone, but no significant difference in overall survival was observed. The study concludes that perioperative chemotherapy should remain the reference treatment for patients with resectable liver metastases from co...
The study found that nab-paclitaxel plus gemcitabine led to significantly improved overall survival and progression-free survival compared to gemcitabine alone. Participants who received nab-paclitaxel also experienced a delay in tumor growth and higher survival rates, with 35% surviving over 1 year.
Treatment with gemcitabine for 6 months significantly improved overall survival (22.8 months vs. 20.2 months) and disease-free survival (13.4 months vs. 6.7 months) in patients after pancreatic cancer surgery. The study demonstrated a 10.3% increase in 5-year overall survival rate.
A nationwide study in Denmark found an increase in bystander cardiopulmonary resuscitation (CPR) and subsequent survival rates, with a significant rise in 30-day and 1-year survival rates. Bystander CPR was positively associated with improved outcomes.
A study of Stage T1aN0 breast cancer patients found no significant increase in deaths from cardiac disease or secondary malignancies among those receiving external beam radiation therapy (XRT). Women who received XRT had better survival rates and fewer deaths from all causes compared to non-XRT groups.
A prospective cohort study of 81,697 racially diverse adults found that lung cancer survival between black and white patients was similar when demographic factors and smoking were controlled. The study aimed to address racial disparities in lung cancer survival rates.
A study led by UT Southwestern Medical Center researchers found that total tumor measurements greater than 3 inches predict shorter survival times in advanced lung cancer patients. Patients with larger tumors live an average of 9.5 months, compared to 12.6 months for those with smaller tumors.
A new study published in the American Journal of Transplantation found that obese kidney failure patients who receive a kidney transplant can live longer than non-obese patients. The survival benefit is lower for severely obese individuals, but improved early post-transplant care may help mitigate this risk.
A study of 5-year survival rates among black and white women with breast cancer found that black women continued to have a lower rate of survival. The difference was largely attributed to factors such as poorer health at diagnosis and more advanced disease, rather than treatment differences.
A randomized clinical trial found that combination therapy using vasopressin-epinephrine during cardiopulmonary resuscitation and corticosteroid supplementation improved survival to hospital discharge with a favorable neurological score. This study suggests increased efficacy of the combination therapy compared to epinephrine alone dur...
Researchers tracked 80 commercial honey bee colonies over 10 months and found that those with queens who had mated at least seven times were 2.86 times more likely to survive. This suggests that genetic diversity is crucial for the survival of honey bee colonies.
The EORTC 62024 trial found that adjuvant imatinib impacts short-term freedom from relapse in patients with localized, surgically resected, high/intermediate-risk GIST. The trial showed a non-statistically significant trend in favor of the adjuvant arm for Imatinib failure-free survival.
A study published in JAMA Internal Medicine found that hospitals with higher case-survival rates for cardiac arrests also had lower incident rates. The research analyzed data from 358 hospitals and identified a correlation between preventing cardiac arrests and survival rates.
Scientists have identified a new protective mechanism that could increase cell survival after stroke, highlighting the importance of SUMOylation in promoting nerve cell adaptation and survival. The discovery may lead to new therapies for stroke and other brain diseases.
Researchers found that a combination of chemoradiation therapy and surgery improves overall survival in stage 3 non-small cell lung cancer patients. Five-year survival rates were twice as high for those who received chemoradiation followed by surgery compared to those who only had chemoradiation.
Researchers found that combining CT imaging findings with baseline serum lactate dehydrogenase levels can accurately predict patient survival. Patients with low baseline serum LDH and evidence of tumor devascularization on their initial post-therapy CT scans are likely to have a favorable response to therapy.
A study of over 310,000 bowel cancer patients in six countries found that UK patients were more likely to be diagnosed at a later stage than others, resulting in lower survival rates. Improved diagnostic investigation and treatment are seen as key factors to increase UK survival rates.
A study published in the Journal of the National Cancer Institute found that Medicare spending for advanced cancer patients does not correlate with survival rates. Despite significant regional differences in spending, researchers discovered a strong link between higher spending and more frequent hospital visits.
Researchers found that patients with metastatic gastric cancer who underwent both surgery and radiation had better survival rates than those receiving one or no treatment. Radiation therapy also showed promise in reducing symptoms such as pain, obstruction, and bleeding from gastric tumors.